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Abstract: Niacin, also known as nicotinic acid, is an organic compound that has several cardio-
beneficial effects. However, its use is limited due to the induction of a variable flushing response 
in most individuals. Flushing occurs from a niacin receptor mediated generation of prostaglandins 
from arachidonic acid metabolism. This study examined the ability of docosahexaenoic 
acid, eicosapentaenoic acid, and omega-3 polyunsaturated fatty acids (PUFAs), to attenuate 
niacin-induced prostaglandins in THP-1 macrophages. Niacin induced both PGD2 and PGE2 
generation in a dose-dependent manner. Niacin also caused an increase in cytosolic calcium 
and activation of cytosolic phospholipase A2. The increase in PGD2 and PGE2 was reduced by 
both docosahexaenoic acid and eicosapentaenoic acid, but not by oleic acid. Omega-3 PUFAs 
efficiently incorporated into cellular phospholipids at the expense of arachidonic acid, whereas 
oleic acid incorporated to a higher extent but had no effect on arachidonic acid levels. Omega-3 
PUFAs also reduced surface expression of GPR109A, a human niacin receptor. Furthermore, 
omega-3 PUFAs also inhibited the niacin-induced increase in cytosolic calcium. Niacin 
and/or omega-3 PUFAs minimally affected cyclooxygenase-1 activity and had no effect on 
cyclooxygenase -2 activity. The effects of niacin on PGD2 generation were further confirmed using 
Langerhans dendritic cells. Results of the present study indicate that omega-3 PUFAs reduced 
niacin-induced prostaglandins formation by diminishing the availability of their substrate, as well 
as reducing the surface expression of niacin receptors. In conclusion, this study suggests that 
the regular use of omega-3 PUFAs along with niacin can potentially reduce the niacin-induced 
flushing response in sensitive patients.
Keywords: flushing, prostaglandin E2, phospholipids, GPR109A, cardiovascular, docosa-
hexaenoic acid, arachidonic acid
Introduction
Nicotinic acid (niacin) is a water soluble vitamin that has been widely used in the 
prevention of cardiovascular disease.1,2 The Coronary Drug Project Study reported that 
niacin reduced nonfatal myocardial infarction by 24% and stroke by 22%.3 Some of the 
general cardio-beneficial effects of niacin at a dose of 1.5 g/day include the reduction 
of total cholesterol, triglycerides, very-low-density lipoprotein, low density lipoprotein 
(LDL), and lipoprotein(a) by 20%.4–7 Niacin has also been shown to effectively increase 
high-density lipoprotein (HDL) by approximately 20%.8,9 These cardio-beneficial 
effects of niacin are mediated largely through a receptor-independent mechanism.
Alternative lipid-reducing medications are statins, best known for their 
LDL-cholesterol lowering effects. Niacin, in contrast, is the most effective, clinically 
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available agent for increasing HDL-cholesterol. The combined 
use of niacin and statins is recommended for improved 
outcomes of cardiovascular events.10–14 For example, an 
HDL-Atherosclerosis Treatment Study15 (HATS) reported 
that a combined treatment of simvastatin plus niacin 
resulted in significant regression of angiographic coronary 
atherosclerosis and reductions in the rate of clinical events 
during 2.5 years of follow-up.16 However, a very recent 
Atherothrombosis Intervention in Metabolic Syndrome 
with low HDL/High Triglyceride: Impact on Global Health 
Outcomes (AIM-HIGH) study reported no incremental 
clinical benefits from the addition of niacin to simvastatin 
therapy during a 36-month follow-up period, despite 
significant improvements in HDL cholesterol and triglyceride 
levels.17,18 The outcome of this study decreased enthusiasm 
for the combined use of niacin and statins. In addition to this, 
niacin use is limited by the majority of patients experiencing a 
“flushing response” that is characterized by severe reddening 
of the skin, itching, and tingling, which leads many patients 
to discontinue use.19,20 Several studies have shown that 
flushing occurs in response to the vasodilatory effects of 
prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2), and 
their metabolites, which are elevated after treatment with 
niacin.21–23 Recently, it has been shown that the epidermal 
Langerhans cells are one of the cell types responsible 
for niacin-induced PGD2 release.24,25 The niacin-induced 
flushing appears to be initiated through a receptor-mediated 
process.26–28 For example, mice deficient in PUMA-G, a 
murine niacin receptor, failed to show a niacin-induced 
increase in ear blood flow (a measure of niacin flush).29 
These investigators have also demonstrated that mice lacking 
PGD2 and PGE2 receptors had reduced flushing responses.29 
Furthermore, other evidence also suggests that PGD2 acting 
through the DP1, a subtype of PGD2 receptor, and PGE2 
acting via type 2 and type 4 PGE2 receptors, mediates the 
niacin-induced flushing response.29,30 Recent studies have 
demonstrated that Langerhans dendritic cells respond to 
niacin with a transient increase in the cytoplasmic Ca2 
concentration and have suggested that Gi (GTP binding 
protein) is activated through the niacin receptor.25 It is well 
known that an increase in the cytoplasmic Ca2+ concentration 
causes activation of phospholipase A2 (PLA2), which liberates 
arachidonic acid (AA) from membrane phospholipids. 
AA can be further metabolized to PGD2 and PGE2 by the 
ubiquitously expressed type 1 cyclooxygenase (COX) 
and both PGD2 and PGE2 synthases, which are present in 
Langerhans dendritic cells. Benyo et al25 suggest that the 
release of PGD2 and PGE2 from niacin-activated cells then 
results in vasodilation in the dermal papillae of the upper 
dermis layer, where the Langerhans cells are localized. This 
sensitization of epidermis by PGD2 and PGE2 results in the 
characteristic flushing response.
Both epidemiological31–33 and prospective randomized 
clinical trials34–36 have reported a decrease in morbidity 
and mortality from heart disease in patients with diets 
supplemented with omega-3 polyunsaturated fatty acids 
(PUFAs). Two particular omega-3 PUFAs are of inter-
est: eicosapentaenoic acid (EPA; 20:5, omega-3) and 
docosahexaenoic acid (DHA; 22:6, omega-3).
Omega-3 PUFAs improve the plasma lipid profile. 
Harris37 concluded that omega-3 PUFAs generally lowered 
triglycerides (TG) by 25%–28% in an analysis of 72 human 
trials, where normal subjects or hypertriglyceridemic 
patients were given 7 g or less of omega-3 PUFAs/day 
for at least a 2 week period. Harris37 further noted that 
omega-3 PUFAs were able to lower lipoprotein cholesterol 
in animal studies, but there was only a minor impact on 
lipoprotein cholesterol levels in human studies. Another 
study by Mori et al also observed similar findings in mildly 
hypertriglyceridemic patients. Intake of omega-3 PUFAs 
(4 g/day for 6 weeks) reduced TG levels by 18%–20% but 
had a minimal impact on low-density lipoprotein cholesterol 
or high-density lipoprotein cholesterol (HDL-C).38 In contrast 
to these studies, long-term treatment of hypertriglyceridemic 
patients with omega-3 PUFAs (4 g/day for 16 weeks) led 
to a significant reduction in TG by 47%, while TG levels 
rose by 16% with a placebo (corn oil). This omega-3 PUFA 
effect was associated with a decrease in ratios of total 
cholesterol to HDL (20%) and a modest increase in high-
density lipoprotein cholesterol (13%).39 Similar results were 
also reported in another study where hypertriglyceridemic 
patients were treated with omega-3 PUFAs (4 g/day) for 
6 months.40 It appears from different studies41 that higher 
levels of omega-3 PUFAs for longer durations have beneficial 
effects on the plasma lipid profile.
In addition to their effects on the lipid profile, omega-3 
PUFAs also exert many cardio-beneficial effects via their 
involvement in several cellular processes. The incorporation of 
omega-3 PUFAs into cellular membranes changes the nature 
of the substrate for phospholipases. PLA2 is a physiologically 
important enzyme. Its activity is stimulated by niacin 
through phospholipase C-mediated calcium mobilization.42 
Cytosolic PLA2 (cPLA2) catalyzes the hydrolysis of fatty 
acids from the sn-2 position of membrane phospholipids, 
resulting in the production of proinflammatory AA-derived 
eicosanoids and platelet-activating factors.43 Not much is 
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known about the direct regulatory effect of omega-3 PUFAs 
on cellular PLA2 activity. However, omega-3 PUFAs are 
easily incorporated into membrane phospholipids on the 
sn-2 position, where AA is usually present. Cytosolic PLA2 
hydrolyzes phospholipids containing omega-3 PUFAs, and 
then generates free DHA or EPA. DHA, EPA, and AA all 
compete for COX and lipooxygenase enzymes; however, 
AA is the strongest substrate of the three.44,45 It is therefore 
possible that omega-3 PUFAs can effectively reduce the 
generation of AA-derived proinflammatory eicosanoids 
including PGD2 and PGE2. Furthermore, DHA is a unique 
fatty acid, because it significantly alters basic properties of 
cell membranes, including acyl chain order and fluidity, phase 
behavior, elastic compressibility, ion permeability, fusion, 
rapid flip-flop, and resident protein function.46 Similarly, 
recent studies have demonstrated that several signaling 
proteins, including surface receptors, are enriched in lipid 
rafts and can be displaced from membrane rafts by both DHA 
and EPA.47,48 Various possible mechanisms for niacin-induced 
PGs formation are outlined in Figure 1.
The objective of this study was to investigate if omega-3 
PUFAs are capable of inhibiting the niacin-induced PGD2 
and PGE2 generation. To test the “proof of the principle,” 
differentiated macrophages were used, as it has been shown 
that macrophages are capable of responding to niacin in a 
similar fashion to that of Langerhans cells.49 Experiments 
on human cultured epidermal Langerhans cells were also 
performed to further confirm the results. Niacin treatment 
caused generation of both PGD2 and PGE2 in macrophages, 
but induced formation of only PGD2 in Langerhans 
cells. Omega-3 PUFAs reduced AA levels in the cellular 
membranes and also reduced surface expression of niacin 
receptors. This results in an attenuation of niacin-induced 
PGD2 and PGE2 synthesis.
Figure 1 Proposed cellular mechanism for Niacin-induced prostaglandins formation.
Notes: Niacin binding to its receptor, gPR109A, causes influx of calcium (Ca2+) through voltage gated channels. Ca2+ binds to cPLA2, which subsequently phosphorylated by 
cellular kinases and translocated to plasma membrane.  Phospholipids containing AA, EPA, or DHA are degraded into free fatty acids by the action of cPLA2. COX-1 and -2 
catalyze oxygenation of AA into 2-series Pg and TXA and oxygenation of EPA into 3-series Pgs and TXA.  DhA is not a substrate for COX-1; however, in endothelial cells 
COX-2 enzymes convert EPA and DhA into hydroxy fatty acids in the presence of aspirin.  These are released from the endothelium and are rapidly converted by 5-lOX 
in adherent leukocytes into bioactive compounds termed as resolvins (resolution phase interaction product). Resolvins derived from EPA are designated as E series (RvE) 
and those derived from DHA are termed as D series.  
Abbreviations: 5-lipooxygenase, 5-lOX; AA, arachidonic acid; COX-1 and-2, Cyclooxygenase-1 and-2; cPlA2, cytosolic phospholipase A2; DhA, docosahexaenoic acid; 
EPA, eicosapentaenoic acid; Pg, prostaglandins; TXA, thromboxanes. 
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Materials and methods
Materials
Niacin was obtained from Sigma-Aldrich (St Louis, MO). 
PGD2 and PGE2 monoclonal enzyme immunoassay (EIA) 
kits came from the Cayman Chemical Company (Ann 
Arbor, MI). COX Fluorescent Activity Assay Kits were 
also purchased from Cayman Chemical. Phycoerythrin-
conjugated rat monoclonal anti-human HM74A/GPR109A 
and Rat IgG Isotype Control-PE were obtained from R&D 
Systems   (Minneapolis, MN). THP-1 or Human Acute Mono-
cytic   Leukemia cells were purchased from American Type 
  Culture Collection (Manassas, VA). Langerhans dendritic 
cells expressing CD1a, MHC class II, and Birbeck gran-
ules, were obtained from MatTek Corporation (Ashland, 
MA).   Diisopropyl fluorophosphate and sodium fluoride 
were from Sigma Chemical Co (St Louis, MO). Phorbol-
12-myristate-13- acetate was acquired from Calbiochem 
(San Diego, CA).
Cell culture and differentiation  
of THP-1 macrophages
THP-1 human monocytic cell line was maintained in 
RPMI 1640 media supplemented with L-glutamine, 
25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid), 10% fetal bovine serum (FBS), and 1% 
penicillin-streptomycin-antimycotic (100X; GIBCO, Grand 
Island, NY). Cells were maintained at 37°C and 5% CO2. 
To initiate differentiation, the cells were plated at near 
90% confluence in serum-free RPMI 1640 (GIBCO) with 
25 nM phorbol-12-myristate-13-acetate for 48 hours at 
37°C and 5% CO2. Differentiation was verified via bright-
field microscopy as well as Western blot analysis of CD36 
expression.
Culturing of Langerhans cells
Freshly isolated human dendritic/Langerhans cells were 
obtained from MatTek Corporation (Ashland, MA) in a T-10 
flask. Cell suspension was centrifuged at 800 xg; cells were 
re-suspended, and then plated at a density of 40,000 cells per 
well in a 96-well plate in dendritic-cells maintenance media 
(DC-MM) supplemented with 5% FBS and a proprietary 
mixture of cytokines to maintain the dendritic cell pheno-
type as per the supplier’s instructions. Cells were allowed 
to attach overnight in an incubator maintained in 37°C and 
5% CO2. Cells were then treated with niacin and/or fatty 
acids as described in the following sections.
Cell growth assay
Stock solutions (1 mM) of DHA, EPA, and oleic acids (OLA) 
were prepared by complexing with fatty acid-free bovine 
serum albumin (BSA).4 Varying concentrations (0, 12.5, 
25, 50, 75, and 100 µM) of fatty acids were used to treat the 
THP-1 derived macrophages. Cell viability was tested using 
the WST-1 assay. The assay was performed according to the 
manufacturer’s instructions (Roche, Indianapolis, IN).
Lipid extraction analysis
THP-1 monocytes (5 × 106) were differentiated in a T-75 
flask for 48 hours. The resulting macrophages were treated 
with 0, 12.5, 25, 50, 75, and 100 µM DHA, EPA, or OLA 
for 24 hours in RPMI 1640 supplemented with L-glutamine, 
25 mM HEPES, 5% FBS, and 1% penicillin-streptomycin-
antimycotic at 37°C and 5% CO2. The cells were harvested 
by trypsinization and centrifuged at 800 xg for 5 minutes and 
then washed in phosphate buffered saline (PBS) containing 
1% fatty-acid free BSA. The cells were re-suspended and 
then lysed in PBS by sonicating on ice. An internal standard 
(C23:0) was added to 500 µl of cell lysate and a portion 
of the remaining 100 µl was used to establish a protein 
concentration in order to normalize fatty acid content to 
the amount of protein present. Lipids were extracted with 
chloroform: methanol (2:1) using the Folch method50 
and fatty acids were converted into methyl esters at room 
temperature for 24 hours as described previously.51 The fatty 
acids were separated on a gas chromatography system 
equipped with an auto sampler, flame ionizing detector 
(GC2010; Shimadzu Corporation, Kyoto, Japan), and a 
Zebron ZB-WAX plus column (100 m, 0.25 mm ID, 0.25 m; 
Phenomenex, Torrance CA). The oven temperature increased 
from 30°C (2 minute hold) to 180°C at 20°C/minute (2 minute 
hold) to 207°C at 4°C/minute (3 minute hold) to 220°C at 
2°C/minute (2 minute hold) to 240°C at 2°C/minute (2 minute 
hold). The flame ionization detector was used at 250°C to 
detect the resolved fatty acids peaks, which were identified 
using authentic standards (Restek Corp, Bellefonte, PA). 
Data was analyzed with Shimadzu’s GC solutions software 
(v2.30.00).
Prostaglandin D2 and E2 EIA assay
Prostaglandin D2 and E2 content in the culture media were 
measured using the competitive EIA kit from Cayman Chemi-
cal (Ann Arbor, MI). The assay was carried out according 
to the manufacturer’s protocol. Briefly, THP-1 differentiated 
macrophages (3 × 104) or Langerhans cells (4 × 104) were 
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treated with DHA, EPA, and OLA in 96 well plates in dupli-
cate for 24 hours in RPMI-1640 containing 5% FBS and 1% 
penicillin-streptomycin-antimycotic (100X) at 37°C and 
5% CO2. After washing with PBS containing 0.1% bovine 
serum albumin, the cells were treated with varying concentra-
tions of niacin for 30 minutes. The supernatant (50 µl) was 
then analyzed for the presence of prostaglandins.
Niacin receptor expression
THP-1 differentiated macrophages (1 × 106) were treated with 
DHA, EPA, or OLA for 24 hours. The cells were scraped 
with a rubber policeman and washed in PBS containing 
0.5% bovine serum albumin and finally resuspended in 
50 µl of this labeling buffer. Cells were then labeled with 
0.5 µg phycoerythrin-conjugated GPR109A antibody for 
45 minutes. The cells were washed twice with PBS containing 
0.5% bovine serum albumin. To ensure specificity of the 
antibody, an isotype control was established for each sample. 
Analysis was performed on a FACSCalibur flow cytometer 
(Becton Dickenson, San Jose, CA) at a 488 nm wavelength. 
The results indicate the mean fluorescent intensity of the 
THP-1 cells.
Determination of calcium mobilization
THP-1 macrophages, treated with fatty acids for 24 hours, 
were loaded with fura-2 acetoxy-methyl ester (fura 2-AM). 
Briefly, cells (1 × 107) were incubated in Hanks’ balanced 
salt solution (HBSS) in the presence of 5 µM fura-2 acetoxy-
methyl ester for 15 minutes at 37°C. After incubation, cells 
were washed twice with modified (Ca2+ and Mg2+ free) 
HEPES-buffered (1 mg/ml) HBSS (pH 7.2) and finally 
resuspended in the same buffer (prewarmed at 37°C). 
Cells (1 × 106) were preincubated for 1 minute in modified 
HEPES-buffered HBSS in a temperature-controlled Perkin-
Elmer LS50B luminescence spectrometer (Perkin-Elmer 
Ltd, Beaconfield, England) to determine baseline excitation 
fluorescence 340/380 nm ratios (R) at 510 nm emission. 
Cells were stimulated with niacin (3 mM) to determine rela-
tive alterations in R due to intracellular release of calcium 
by continuously monitoring (5 minutes) at 340 and 380 nm 
excitation.
Western blot analysis  
of phosphorylated-cPLA2
Lysates of  THP-1 macrophages treated with varying 
concentrations of niacin were prepared in radioimmuno-
precipitation assay lysis buffer (Millipore, Temecula, CA) 
containing 2.5 mM diisopropyl fluorophosphate, 100 mM 
sodium fluoride and protease inhibitors cocktail (Roche, 
Indianapolis, IN). Proteins in the samples were separated 
by sodium dodecyl sulfate page electrophoresis and trans-
ferred onto nitrocellulose membranes. The membranes 
were blocked with 10% western blocking reagent (Roche, 
Indianapolis, IN) in 1× Tris-Buffered Saline-Tween at room 
temperature for 1 hour. The membranes were then incubated 
overnight at 4°C with the phospho-cPLA2 primary antibody 
(Cell Signaling Technologies, Danvers, MA) at 1:1000 in 
1× Tris-Buffered Saline-Tween. Blots were developed using 
biotinylated secondary antibodies linked to horse radish 
peroxidase (GE Healthcare, Little Chalfont, UK) and the 
signal was detected using enhanced chemi-luminescence 
plus western blocking detection reagents (Amersham, Little 
Chalfont, UK).
COX activity EIA assay
The total COX activity and COX-1 and COX-2 content in the 
culture media were measured using the fluorescent activity 
assay kit from Cayman Chemical. THP-1 differentiated 
macrophages (1.5 × 106) were treated with 50 µM DHA, 
EPA, or OLA for 24 hours at 37°C and 5% CO2. Cells 
were scraped using a rubber policeman. The cells were 
sonicated in 100 mM Tris HCl (pH 7.5) containing protease 
inhibitors (Sigma). The lysate was centrifuged at 10,000 ×g 
for 15 minutes at 4°C and the supernatant was transferred 
to another micro-centrifuge tube. 10 µl of each sample was 
transferred to a 96 well plate and the assay was carried out 
according to the manufacturer’s protocol. The plate was 
analyzed using a fluorescent well plate reader (Perkin-Elmer). 
The total COX, COX-1 and COX-2 activities were determined 
against a standard curve and using the COX-1 inhibitor 
SC-560 and the COX-2 inhibitor DuP-697.
Results
Fatty acid treatment and cell growth
To ensure cell survival during experiments, THP-1 macrophages 
were exposed to 0–100 µM DHA, EPA, and OLA. DHA 
treatment at concentrations below 50 µM did not induce any 
substantial effect on cell viability; however, concentrations 
at 75–100 µM showed a reduction in cellular viability by 
20%–25% (P . 0.05) when compared to the non-treated 
control (data not shown). EPA-treatments showed less impact 
on THP-1 viability, with less than a 10% decrease (non-
significant) at 100 µM. The OLA-treatment resulted in only 
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,2% decrease in cell viability at the highest concentration of 
100 µM. Based on these results, the authors performed most 
subsequent experiments at 50 and 75 µM fatty acids.
Omega-3 PUFAs reduced niacin-induced 
PgD2 and PgE2 production
To test the effect of the omega-3 PUFAs on niacin induced 
PGD2 and PGE2 release in macrophages, THP-1 cells were 
treated with DHA, EPA, and OLA prior to exposure to 
increasing concentrations of niacin. Niacin increased both 
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and (C) OlA for 24 hours before being exposed to varying concentrations of niacin 
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are the means ± the standard deviations of duplicate experiments. 
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PGD2 and PGE2 formation in a dose dependent manner. 
PGD2 formation was greatly increased by 2–7-fold in a dose 
dependent manner on niacin-treatment (Figure 2), whereas 
the effect of niacin on PGE2 formation resulted in only a 
moderate 1.5–2 fold increase (Figure 3). Both DHA and EPA 
reduced basal as well as niacin-induced increases in PGD2 
and PGE2formation (Figure 2A and B and Figure 3A and B, 
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respectively). In contrast, OLA treatment resulted in further 
enhancement of basal, as well as niacin-induced PGD2 and 
PGE2 formation (Figures 2C–3C).
Omega-3 PUFAs alter FA profile
The authors next examined the incorporation of fatty acid in 
THP-1 cells. An analysis of membrane fatty acid composition 
suggested that DHA treatment increased the incorporation 
of DHA in the phospholipids in a dose dependent manner 
(2 to 168 µg/mg protein). Furthermore, the increased DHA 
levels in phospholipids occurred at the expense of AA, 
whose levels decreased from 24 to 13 µg AA/mg protein 
(Figure 4A). EPA-treatment subsequently increased EPA 
incorporation in phospholipids in a dose dependent   manner 
(2 to 190 µg/mg protein) (Figure 4B). EPA incorporation 
into membrane phospholipids also occurred at the expense 
of AA and resulted in its reduction from 25 to 9 µg AA/mg 
protein (Figure 5). Although basal levels of OLA were 
substantially greater than DHA or EPA, OLA amounts sig-
nificantly increased in a concentration dependent manner 
(51 to 391 µg/mg protein); however, OLA incorporation 
had a minimal effect on AA displacement (Figure 4C).
Omega-3 PUFAs down regulate  
the gPR109A receptor
The authors analyzed the effects of DHA, EPA, and OLA on 
the expression of the niacin receptor, GPR109A, using flow 
cytometry. Data in Figure 5 indicate that DHA-treatment at 
50 µM showed a 60% decrease in GPR109A expression, 
while 75 µM DHA further decreased the expression to 75% 
fewer receptors than compared to the control. 50 µM EPA 
reduced GPR109A receptor expression by 67%; however, 
75 µM EPA did not further reduce its expression. In contrast, 
OLA treatment did not result in a significant reduction of 
niacin receptor expression.
Effect of omega-3 PUFAs on cellular 
calcium release
The authors further analyzed the effect of niacin on down-
stream calcium mobilization (Figure 6). In untreated cells 
niacin increased intracellular calcium (red line) in a time 
dependent manner. However, niacin-induced intracellular cal-
cium increases were not observed when cells were   pretreated 
with DHA (blue line), EPA (green line), or OLA (pink line).
Niacin induces cPLA2 activation
One of the downstream targets for Ca2+ is cPLA2, whose 
activity causes the release of AA, a substrate for PGD2 and 
PGE2 synthesis. Therefore, the effect of niacin treatment 
on cPLA2 activity was measured. Earlier experiments 
(Figure 4) indicate that DHA and EPA incorporated into 
phospholipids at the expense of AA. As a result, it was 
realized that measuring AA release by niacin in DHA and 
EPA-treated cells is not an appropriate assay for PLA2 activity. 
Hence, the phosphorylation of PLA2 by niacin was used as a 
measure of PLA2 activity. Results shown in Figure 7 indicate 
that niacin at 1.5 mM caused a maximal 2-fold increase in 
cPLA2 phosphorylation at 30 minutes of incubation. Higher 
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Figure 4 Fatty acid incorporation into phospholipids of THP-1 macrophages. 
Notes:  THP-1  macrophages  were  treated  with  increasing  concentrations  of 
(A) DhA, (B) EPA or (C) OlA for 24 hours. lipids were isolated and fatty acid 
concentrations were determined by gas chromatography as described in the text. 
Notes: Values are the mean ± the standard deviation of triplicates. Results are 
analyzed using Student’s t test. *P , 0.01 compared to non-supplemented cells. 
Abbreviations:  AA,  arachidonic  acid;  DhA,  docosahexaenoic  acid;  EPA,  eico-
sapentaenoic acid; PgD2, prostaglandin D2; OlA, oleic acid.
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concentration of niacin at 3 mM also induced a 2-fold increase 
in phosphorylation of cPLA2 at 10 minutes of incubation 
which did not change on a longer incubation (30 minutes).
Effect of omega-3 PUFAs  
on COX activity
The authors observed that niacin itself has no effect on COX-1 
activity (Table 1). DHA treatment alone slightly reduced 
COX-1 activity, which was further decreased when DHA-
treated cells were stimulated with niacin. EPA treatment alone 
had no effect COX-1 activity; however, activity was decreased 
when EPA-treated cells were stimulated with niacin. OLA 
also had no effect on COX-1 activities, and this activity was 
also decreased when OLA-treated cells were stimulated with 
niacin. THP-1 cells also showed very little COX-2 activity that 
was not affected by niacin or fatty acid treatment (Table 1).
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Omega-3 PUFAs also regulate niacin-
induced PgD2 and PgE2 production  
in Langerhans cells
After the initial completion of this study of THP-1 cells, 
the authors evaluated the effects of omega-3 PUFAs in the 
more disease relevant epidermal Langerhans cells. Data in 
Figure 8 show that untreated Langerhans cells exhibited a 
dose-dependent increase in PGD2 production with increas-
ing concentrations of niacin. When treated with 50 µM 
DHA, the PGD2 production decreased to 71% and 42% 
at 1.5 and 3 mM concentrations of niacin, respectively. 
EPA decreased PGD2 production to 53% and 85% at 1.5 
and 3 mM concentrations of niacin, respectively. PGE2 
production showed very little change with both concentra-
tions of niacin (data not shown).
Discussion
Several studies have reported that niacin’s receptor-mediated 
enhanced release of PGD2 from tissue macrophages causes 
flushing, particularly by epidermal Langerhans dendritic 
cells.22,24,25,30,49,52 Several mechanisms have been proposed 
to reduce flushing in patients on niacin treatment, including 
reducing absorption of niacin, blocking DP1 receptors, and 
preventing production of prostaglandins.53 Initial attempts 
to make slow release niacin, which effectively reduced 
flushing, failed because of its hepatotoxicity.54,55 Conversely, 
an extended- release niacin (rates between immediate release 
and slow release niacin) formulation (Niaspan, Abbott 
Park, IL) improved CHD outcome and had no hepatotoxic 
effects, but continued to cause flushing in patients when given 
higher doses (1–2 g/day) in combination with statins.56–58 
A selective DP1 antagonist, laropiprant, was developed to 
further mitigate the niacin-induced flushing and has shown 
promise to allow 1–2 g/day dosing regimen of niacin.59 
Although laropiprant is a potent inhibitor of DP1, it does 
not eliminate flushing in all patients,9 suggesting that other 
pathways may be involved in the residual flushing. Inhibition 
of prostaglandin synthesis by blocking the activities of COX 
enzymes with aspirin,60–62 indomethacin,63 ibuprofen,53 and 
naproxen23 has also been shown to decrease niacin-induced 
flushing. In the present study, another approach was used to 
prevent production of prostaglandins. Since prostaglandins 
are synthesized directly from AA, an omega-6 PUFA, it was 
hypothesized that replacing cellular content of AA by ome-
ga-3 PUFAs (DHA and EPA) would reduce niacin-induced 
PGD2 synthesis. The effects of omega-3 PUFAs were tested 
in differentiated THP-1 macrophages, as these were easy to 
maintain in culture and also reported to respond in a similar 
fashion as that of the epidermal Langerhans cells.49 OLA, an 
omega-9 monounsaturated fatty acid, was also included to 
demonstrate the specificity of omega-3 PUFA effects.
This study’s data has shown that EPA and OLA did not 
significantly impact THP-1 macrophage growth; however, 
DHA did exhibit modest growth inhibition of these cells at 
higher concentrations ($75 µM). As previously reported 
by several investigators, the data also clearly demonstrated 
that niacin induced PGD2 synthesis in a dose-dependent 
manner. Furthermore, both DHA and EPA effectively 
reduced basal, as well as niacin-induced PGD2 synthesis. 
In contrast, OLA alone stimulated PGD2 release, which 
was further enhanced in the presence of niacin. The effect 
of niacin on PGE2 synthesis was also measured. The extent 
of PGE2 synthesis by niacin was substantially lower than 
that of PGD2 synthesis. However, both DHA and EPA were 
able to reduce niacin-induced PGE2 synthesis, whereas 
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Figure 6 Effect of fatty acids on calcium mobilization in THP-1 macrophages. 
Notes: Macrophages were treated with 50 µM DhA, EPA, and OlA for 24 hours. Cells were labeled with Fura 2-AM, and the change in ratio of fluorescence intensity at 
340/380 (R) was monitored as described in the text. Results show a representation from three experiments. 
Abbreviations: DhA, docosahexaenoic acid; EPA, eicosapentaenoic acid; OlA, oleic acid.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
45
Omega-3 fatty acids and niacin-induced flushingJournal of Inflammation Research 2012:5
OLA had a stimulatory effect. Production of eicosanoids 
can be regulated by the availability of their substrate, AA, 
in phospholipids.Therefore the effect of fatty acids on AA 
content in membrane phospholipids was measured. The data 
clearly indicated that both DHA and EPA incorporated into 
cellular phospholipids at the expense of AA. This result is 
consistent with the authors46 previous reports that omega-3 
PUFAs effectively decrease cellular AA content. However, 
it is notable that OLA, despite its substantial incorporation 
into phospholipids, had no effect on AA levels and exhibited 
a stimulatory effect on PGD2 and PGE2 synthesis. The data 
indicates (not shown) that OLA mostly incorporated at the 
expense of stearic and palmitic acid (18:0 and 16:0, respec-
tively), and therefore has no impact over AA incorporation. 
Furthermore, OLA is not a substrate for the COX pathway 
and, therefore, it does not compete with AA for eicosanoid 
generation. It is not clear from the present investigation why 
OLA had a stimulatory effect on PGD2 and PGE2 synthesis. 
It is possible that the released stearic and/or palmitic acid 
induced COX-1 or -2 activities. Clearly, further investigation 
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Figure 7 Niacin induces cPLA2 activation in THP-1 macrophages. 
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described in the text. (B) Data is the densitometry analysis of bands and reported as the mean ± SD of ratios of cPlA2/gAPDh of at least three determinations. Results are 
analyzed using ANOVA, followed by pair-wise comparisons with the Bonferroni adjustment. *P , 0.01 compared to niacin treatment controls. 
Abbreviations: cPLA2, cytosolic phospholipase A2.
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is needed to understand the effect of OLA on PGD2 and 
PGE2, which was beyond the scope of this study.
Enrichment of omega-3 PUFAs in cellular membranes 
often results in changes in the surface expression of mem-
brane proteins, including receptors.46,48 Therefore, the surface 
expression of GPR109A, a niacin receptor, was examined. 
The authors found that both DHA and EPA reduced sur-
face expression of the niacin receptor, whereas OLA was 
  ineffective. Diminished GPR109A expression could result 
in a reduction in niacin-induced flushing. The present study 
did not investigate if the reduced expression of GPR109A is 
due to reduced synthesis at the transcriptional or translational 
level, or if it is due to reduced translocation to the surface 
from intracellular storage. It is likely that omega-3 PUFAs 
reorganize lipid rafts48 and therefore affected the translo-
cation of the receptor. The downstream events to niacin 
receptor were then examined. As previously reported,25 
niacin induced an increase in cytosolic calcium, which was 
effectively blocked by both DHA and EPA as well as by 
OLA. Stimulation of cells with niacin caused a gradual rise 
in calcium in the absence of a rapid initial rise. This suggests 
that the rise in calcium was due to influx from extracel-
lular sources rather than release from intracellular stores. 
L-type voltage gated calcium channels that regulate influx 
of calcium from extracellular sources have previously been 
shown to be inhibited by omega-3 PUFAs.64–66 It is therefore 
likely that omega-3 PUFAs inhibited calcium influx through 
inhibiting L-type calcium channels. Other unsaturated fatty 
acids have been shown to act on these channels67 and it is 
therefore possible that OLA also inhibited L-type calcium 
channels in the present study. One of the targets for rising 
cytosolic calcium is activation of cPLA2, which releases AA 
for PGD2 and PGE2 synthesis. The effect of niacin on cPLA2 
activity was accessed by measuring its   phosphorylation. 
The results clearly indicate that niacin-treatment of 
THP-1 cells resulted in cPLA2 phosphorylation, indicating 
that niacin induces PGD2 and PGE2 formation by liberating 
AA from phospholipids. However, when AA is replaced 
by DHA or EPA, niacin-induced cPLA2 activity releases 
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Figure 8 Effect of fatty acids on niacin-induced PgD2 secretion in Langerhans cells. 
Notes: langerhans cells were treated with 50 µM fatty acids for 24 hours before a 30 minute exposure to 1.5 or 3 mM niacin. Concentrations of PgD2 in the medium were 
determined using an EIA kit as per manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI). Values are the means ± the standard deviations of triplicate experiments 
from one preparation of Langerhans cells. 
Abbreviations: EIA, enzyme immunoassay.
Table  1  Effect  of  fatty  acids  on  COX-1  activity  in  THP-1 
macrophages
COX-1 activity 
(nM/min/mg protein)
COX-2 activity 
(nM/min/mg protein)
Niacin Niacin
0 3 mM 0 3 mM
Vehicle 15.5 ± 2.1 16.1 ± 4.2 16.7 ± 6.7   6.9 ± 1.7
DHA 12.7 ± 2.9   9.7 ± 3.8   8.5 ± 5.1   5.3 ± 3.5
EPA 16.0 ± 3.8 10.2 ± 0.6   7.9 ± 4.5 11.8 ± 1.0
OLA 14.9 ± 2.9 11.6 ± 0.8 11.9 ± 2.2 10.3 ± 5.0
Notes: Macrophages were treated with 75 µM DhA, EPA, and OlA for 24 hours 
prior  to  a  30  minute  exposure  to  3  mM  niacin.  COX-1  and  -2  activities  were 
measured according to the kit manufacturer’s specifications. Values are the mean ± 
the standard deviation of triplicates. Results are analyzed using Student’s t-test. No 
statistical difference is found in any treatment group compared to niacin-treated 
controls. 
Abbreviations: COX-1 and-2, cyclooxygenase-1 and-2; cPlA2, cytosolic phospholipase 
A2; DhA, docosahexaenoic acid; EPA, eicosapentaenoic acid; OlA, oleic acid.
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DHA or EPA. Both DHA and EPA compete with AA for 
downstream COX-1 activity.68–71 During the present inves-
tigation, none of the fatty acids had any significant effect 
on COX-1 activity. It is therefore possible that inhibition 
of PGD2 and PDE2 synthesis by DHA or EPA is, to some 
extent, due to a reduction of their substrate, AA. However, 
the effect of EPA and DHA on GPR109A expression, and 
inhibition of niacin-induced calcium release also play a 
role in the reduction of niacin-induced flushing response by 
omega-3 PUFA. Furthermore, it is also possible that DHA 
and EPA directly induced anti-inflammatory effects through 
GPR120, a specific omega-3 fatty acids receptor expressed 
on macrophages;72 however, it is not known if EPA and DHA 
mediated effects through GPR120 regulate pro-inflammatory 
prostaglandin synthesis.
In order to correlate these studies to relevant primary cell 
line, the effect of DHA, EPA, and OLA on niacin-induced 
PGD2 and PGE2 synthesis was also measured in Langerhans 
dendritic cells. Both DHA and EPA were able to inhibit 
niacin-induced PGD2 synthesis, whereas OLA was not effec-
tive. The authors also noticed that EPA and OLA caused a 
basal increase in PGD2 synthesis. The reason for this increase 
is not clear. One possibility is variation in the incorporation 
and metabolism of EPA in the different cell types. In contrast, 
niacin did not increase PGE2 synthesis and fatty acid-treat-
ments had variable responses. However, this study’s results 
are consistent with other studies where niacin enhanced 
only PGD2 production in Langerhans dendritic cells.25,26 
These data suggest that PGD2 plays key a role in mediating 
niacin-induced flushing responses. It is unclear why PGE2 
production is stimulated by niacin in THP-1 cells but not in 
Langerhans cells. Perhaps a second co-factor is required for 
niacin stimulation that is not present in the Langerhans cells. 
Further investigation is required to determine this.
It is important to note that the outcome from the recent 
AIM HIGH study reduces enthusiasm for the use of niacin 
and statin combination therapy; however, it is possible that 
use of omega-3 fatty acids with a combination therapy of 
niacin and statins may be advantageous in improving cardiac 
events. As mentioned above, long term use of omega-3 fatty 
acids would have added benefits on improving LDL/HDL 
ratios and reducing triglycerides. Several pharmaceutical 
companies are aggressively marketing omega-3 fatty 
acids preparations for cardiac benefits. For example, 
preparations such as Crystal EPA-TG (Equateq, Scotland), 
Omevital TG, Omevital TG-Gold, Omevital –TG-ultra and 
Omevital-90%TG (Cognis, UK), Incromega (Croda, Goole, 
UK), and algal-DHA (Martek, Columbia, MD) have been 
developed that have substantially improved contents of 
omega-3 fatty acids than that of commercially available 
menhaden fish oils. In addition to this prescription grade 
omega-3, supplements containing ethyl esters of DHA + EPA 
(Lovaza, GlaxoSmithKline, London, UK) are also available. 
More recently pure ethyl ester preparations of EPA (AMR101, 
Amarin Corporation, Bedminster, NJ) were developed to 
treat patients for high or very high triglyceride levels. These 
preparations supply enriched quantities of omega-3 fatty 
acids higher than typically present in over-the-counter fish 
oil supplements.
Conclusions
The data indicated that omega-3 PUFAs can effectively 
inhibit niacin-induced synthesis of PGD2 and PGE2, the 
key mediators of flushing caused by niacin intake. The 
possible inhibitory mechanisms appear to be diminished 
niacin receptor expression and reduced availability of AA, 
a substrate for PGD2 and PGE2 synthesis. These effects are 
mediated within cellular membranes and are based on the 
enhanced incorporation of omega-3 PUFAs into membrane 
phospholipids. Therefore, this study suggests that regular 
intake of fish, fish oil supplements, prescription grade DHA 
and EPA formulation (GlaxoSmithKline) or other com-
mercially available DHA-, and EPA-enriched preparations, 
will not only be beneficial in reducing the flushing response 
of niacin, but also provide several known cardio-beneficial 
effects.73
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